Tafasitamab: A New Horizon for Follicular Lymphoma Treatment

In an interview with Targeted Oncology, Christina Poh, MD, assistant professor at the University of Washington, Fred Hutchinson Cancer Center, discusses practical implications and considerations with the use of tafasitamab (Monjuvi) for the treatment of follicular lymphoma.

When analyzing various treatment regimens for follicular lymphoma, certain patient subgroups may show greater benefits from a specific regimen over others. However, a key finding regarding the tafasitamab regimen is that it has shown a benefit for all patients, regardless of their disease risk. This is a significant distinction from other regimens, which may not offer the same universal benefit.

Because of this, the tafasitamab regimen can be considered for all patients who would be candidates for a lenalidomide (Revlimid) and rituximab (Rituxan) combination. This is particularly relevant given that tafasitamab has been shown to be superior to the lenalidomide-rituximab combination. Of the 3 drugs, lenalidomide is the one most considered for its potential comorbidities. Physicians evaluate if any of a patient's existing health conditions would be contraindicated with lenalidomide, and if not, the tafasitamab regimen is considered a reasonable and practical option.

The adoption of this regimen is also practical for community providers. Tafasitamab is already approved for diffuse large B-cell lymphoma in combination with lenalidomide, so many providers are already familiar with its use and its adverse event (AE) profile. They are also well-versed in the AE profiles of both lenalidomide and rituximab. In the clinical trial, the addition of tafasitamab did not introduce any new safety concerns, which should make its adoption into standard practice more seamless.

This description was generated with assistance from Google Gemini. It was edited and reviewed by Targeted Oncology staff. If you have any questions about the use of AI, please contact us.